Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer.
Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer.
复制标题
DOI：
10.3892/ol.2016.4513
复制
发表时间：
2016-06
期刊：
影响因子：
2.9
通讯作者：
Hiramatsu Y
中科院分区：
文献类型：
--
作者：
Nakamura K;Nagasaka T;Nishida T;Haruma T;Ogawa C;Kusumoto T;Seki N;Hiramatsu Y
炎症和肿瘤免疫学与多种癌症的预后相关。本回顾性研究的目的是确定中性粒细胞与淋巴细胞比率（NLR），血小板与淋巴细胞比率（PLR），癌抗原125（CA125）浓度，肿瘤反应，体能状态（PS）和接受化疗后复发性卵巢癌患者的生存率之间的关系。与二线化疗前相比，四线化疗前测量的NLR和PLR显著增加（分别为P=0.029和0.049）。通过使用受试者工作特征曲线，确定了治疗前阶段测量的NLR、PLR和CA 125水平的临界值，这些值可预测结局。根据单变量分析，治疗前NLR >3.91、PLR >299.0和PS 2均与不良结局显著相关（分别为P=0.001、0.005和0.021）。根据多变量分析，只有治疗前NLR与不良结局相关（P=0.035）。目前的研究结果表明，治疗前NLR是化疗后复发的卵巢癌患者预后的重要预测因素。
Inflammation and tumor immunology are associated with prognosis in a variety of cancers. The aim of the present retrospective study was to identify associations between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), cancer antigen 125 (CA125) concentrations, tumor response, performance status (PS) and survival of patients that developed recurrent ovarian cancer subsequent to receiving chemotherapy. The NLR and PLR measured prior to fourth-line chemotherapy were significantly increased compared with those measured prior to second-line chemotherapy (P=0.029 and 0.049, respectively). By using receiver operating characteristic curves, the cut-off values were determined for the NLR, PLR and CA125 levels that were measured during the pre-treatment phase, which predicted the outcomes. According to univariate analyses, pre-treatment NLR >3.91, PLR >299.0 and PS 2 were each significantly associated with poor outcomes (P=0.001, 0.005 and 0.021, respectively). According to multivariate analyses, only pre-treatment NLR was associated with poor outcome (P=0.035). The present findings indicate that pre-treatment NLR is an important predictor of prognosis in patients with ovarian cancer that experience recurrence following chemotherapy.